EP2861222A4 - Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof - Google Patents

Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Info

Publication number
EP2861222A4
EP2861222A4 EP13806162.7A EP13806162A EP2861222A4 EP 2861222 A4 EP2861222 A4 EP 2861222A4 EP 13806162 A EP13806162 A EP 13806162A EP 2861222 A4 EP2861222 A4 EP 2861222A4
Authority
EP
European Patent Office
Prior art keywords
disstituted
hepa
dimethoxyphenyl
diene
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13806162.7A
Other languages
German (de)
French (fr)
Other versions
EP2861222A1 (en
Inventor
Charles Shih
Qian Shi
Hui-Kang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allianz Pharmascience Ltd
Original Assignee
AndroScience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/525,941 external-priority patent/US8710272B2/en
Application filed by AndroScience Corp filed Critical AndroScience Corp
Priority to EP19176039.6A priority Critical patent/EP3549581A3/en
Priority to EP16187672.7A priority patent/EP3150203B1/en
Priority to DK16187672.7T priority patent/DK3150203T3/en
Publication of EP2861222A1 publication Critical patent/EP2861222A1/en
Publication of EP2861222A4 publication Critical patent/EP2861222A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
EP13806162.7A 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof Ceased EP2861222A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP19176039.6A EP3549581A3 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
EP16187672.7A EP3150203B1 (en) 2012-06-18 2013-06-17 Compounds with (1e,6e)-1,7-bis-(3,4- dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-di-one structural scaffold,their biological activity, and uses thereof
DK16187672.7T DK3150203T3 (en) 2012-06-18 2013-06-17 COMPOUNDS WITH (1E, 6E) -1,7-BIS- (3,4-DIMETHOXYPHENYL) -4,4-DISUBSTITUTED-HEPA-1,6-DIENE-3,5-DI-ON STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY AND APPLICATIONS THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/525,941 US8710272B2 (en) 2007-01-08 2012-06-18 Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
PCT/US2013/046138 WO2013192091A1 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16187672.7A Division EP3150203B1 (en) 2012-06-18 2013-06-17 Compounds with (1e,6e)-1,7-bis-(3,4- dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-di-one structural scaffold,their biological activity, and uses thereof
EP19176039.6A Division EP3549581A3 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Publications (2)

Publication Number Publication Date
EP2861222A1 EP2861222A1 (en) 2015-04-22
EP2861222A4 true EP2861222A4 (en) 2015-08-05

Family

ID=49769258

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19176039.6A Withdrawn EP3549581A3 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
EP16187672.7A Active EP3150203B1 (en) 2012-06-18 2013-06-17 Compounds with (1e,6e)-1,7-bis-(3,4- dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-di-one structural scaffold,their biological activity, and uses thereof
EP13806162.7A Ceased EP2861222A4 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP19176039.6A Withdrawn EP3549581A3 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
EP16187672.7A Active EP3150203B1 (en) 2012-06-18 2013-06-17 Compounds with (1e,6e)-1,7-bis-(3,4- dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-di-one structural scaffold,their biological activity, and uses thereof

Country Status (14)

Country Link
EP (3) EP3549581A3 (en)
JP (2) JP6392752B2 (en)
KR (1) KR102171469B1 (en)
CN (3) CN110279680A (en)
AU (1) AU2013277423B2 (en)
CA (1) CA2876957C (en)
DK (1) DK3150203T3 (en)
ES (1) ES2775173T3 (en)
HK (1) HK1211211A1 (en)
IN (1) IN2015MN00131A (en)
MX (1) MX2014015936A (en)
NZ (1) NZ703167A (en)
SG (1) SG11201408387YA (en)
WO (1) WO2013192091A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11712418B2 (en) * 2017-05-26 2023-08-01 Bruin Biosciences, Inc. Chemoembolization agents
CN107226783B (en) * 2017-06-20 2019-07-23 武汉工程大学 A kind of lysosome targeting fluorescent probe and preparation method thereof
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
US11135185B2 (en) * 2018-03-23 2021-10-05 Merry Life Biomedical Company, Ltd. Uses of curcumin derivative
JP2020125285A (en) * 2019-01-04 2020-08-20 アリアンツ ファーマサイエンス リミテッド Method for treating neurodegenerative disorder
JP2020117489A (en) * 2019-01-04 2020-08-06 アリアンツ ファーマサイエンス リミテッド Method for treating brain cancer
CN110183320B (en) * 2019-04-15 2021-06-11 四川大学 Polyene diketone antitumor compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088927A2 (en) * 2002-04-17 2003-10-30 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2006044379A2 (en) * 2004-10-15 2006-04-27 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2008085984A1 (en) * 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
WO2009017815A1 (en) * 2007-07-31 2009-02-05 Androscience Corporation Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812408A (en) 1905-08-19 1906-02-13 Roy Ernest Dickerson Educational device for teaching spherics.
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088927A2 (en) * 2002-04-17 2003-10-30 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2006044379A2 (en) * 2004-10-15 2006-04-27 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2008085984A1 (en) * 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
WO2009017815A1 (en) * 2007-07-31 2009-02-05 Androscience Corporation Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN L ET AL: "Antitumor Agents. 250. Design and Synthesis of New Curcumin Analogues as Potential Anti-Prostate Cancer Agents", JOURNAL OF MEDICINAL CHEMISTRY,, vol. 49, no. 13, 1 July 2006 (2006-07-01), pages 3963 - 3972, XP008110105, DOI: 10.1021/JM051043Z *
OHTSU H ET AL: "Antitumor agents 222. Synthesis and anti-androgen activity of new diarylheptanoids", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 11, no. 23, 17 November 2003 (2003-11-17), pages 5083 - 5090, XP008122579, ISSN: 0968-0896, [retrieved on 20031014], DOI: 10.1016/J.BMC.2003.08.029 *
See also references of WO2013192091A1 *

Also Published As

Publication number Publication date
EP2861222A1 (en) 2015-04-22
EP3549581A3 (en) 2020-02-19
CN106220507A (en) 2016-12-14
AU2013277423A1 (en) 2015-01-22
EP3150203A1 (en) 2017-04-05
EP3549581A2 (en) 2019-10-09
SG11201408387YA (en) 2015-01-29
HK1211211A1 (en) 2016-05-20
DK3150203T3 (en) 2020-04-14
KR102171469B1 (en) 2020-10-30
EP3150203B1 (en) 2020-02-19
ES2775173T3 (en) 2020-07-24
AU2013277423B2 (en) 2018-08-09
JP2015520233A (en) 2015-07-16
JP2018135386A (en) 2018-08-30
NZ703167A (en) 2016-09-30
CA2876957A1 (en) 2013-12-27
WO2013192091A1 (en) 2013-12-27
CA2876957C (en) 2021-02-16
IN2015MN00131A (en) 2015-10-16
KR20150023012A (en) 2015-03-04
CN110279680A (en) 2019-09-27
JP6392752B2 (en) 2018-09-19
CN104755076A (en) 2015-07-01
MX2014015936A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
HK1211211A1 (en) Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4- disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof (1e6e)-17--(34-)-44--16-- 35-
HK1203389A1 (en) Amidine substituted beta lactam compounds, their preparation and use as antibacterial agents
IL215799A (en) Quinazolone compounds, pharmaceutical compositions comprising the same and uses thereof
BR112012002349A2 (en) compound and use thereof
BR112012004335A2 (en) compound, pharmaceutical composition, and use of the compound.
IL223983A (en) Heterocyclic alkynyl benzene compounds, medicinal compositions comprising them and uses thereof
IL211584A (en) Macrocyclic pyrimidine compounds, their preparation and use thereof
BRPI0808098A2 (en) 4-ARYL-1,4-DI-HYDRO-1,6-NAPHTHRIDINAMIDS REPLACED AND THEIR USE
BR112012031226A2 (en) compound, compound use, pharmaceutical composition, and pharmaceutical composition use
BRPI0815192A2 (en) Threaded Locking Fastener, and, Threaded Locking Fastener Set
ZA201603272B (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
BR112012005736A2 (en) substituted dihydro benzocycloalkyloxymethyl oxazolapyrimidinones, preparation and use thereof
ES1110832Y (en) DISPOSABLE AND FOLDABLE URINAL.
AR092882A1 (en) 1,2,4-triazin-3,5-dion-6-carboxamides and their use as herbicides
CL2014003525A1 (en) Pharmaceutical composition comprising fimasartan, hydrochlorothiazide and a binder; preparation procedure; its use in the treatment of hypertension.
BRPI0920502A2 (en) cycloundecadepsipeptide compounds and their use as medicines
HK1206348A1 (en) Cyclohexane-1,2-indene-1,2-imidazol compounds and their use as bace inhibitors -12--12- bace
IL251177A0 (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
BRPI0911772A2 (en) compound, pharmaceutical composition, and use of the compound.
SMT201600421B (en) 7-METHYL-2- [4-METHYL-6- [4- (trifluoromethyl) phenyl] pyrimidin-2-IL] -1,7-diazaspiro [4.4] nonan-6-ONE
BRPI0906727A2 (en) Cyclic Azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
BRPI1011736A2 (en) polyolefin composition, its use and article
ZA201304439B (en) Anti-regurgitation and/or anti-gastro-oesophageal reflux composition,preparation and uses
BR112012002311A2 (en) compound, pharmaceutical composition, and use of the compound.
BRPI1009090A2 (en) Compound, prodrug, medicine, methods, and compound use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHIH, CHARLES

Inventor name: WANG, HUI-KANG

Inventor name: SHI, QIAN

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150703

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/121 20060101AFI20150629BHEP

Ipc: A01N 35/02 20060101ALI20150629BHEP

Ipc: A61P 17/02 20060101ALI20150629BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALLIANZ PHARMASCIENCE LTD

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SU, CHING-YUAN.

Inventor name: SHIH, CHARLES

Inventor name: SHI, QIAN

Inventor name: WANG, HUI-KANG

17Q First examination report despatched

Effective date: 20161108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190405